| University of Kentucky Research Foundation Patent applications |
| Patent application number | Title | Published |
|---|
| 20120122943 | Melampomagnolide B Derivatives as Antileukemic and Cytotoxic Agents - Melampomagnolide B is disclosed as a new antileukemic sesquiterpene. A biotin-conjugated derivative of melampomagnolide B was prepared to elucidate its mechanism of action. Prodrugs of Melampomagnolide B are disclosed. | 05-17-2012 |
| 20120118308 | ALTERATION OF TOBACCO ALKALOID CONTENT THROUGH MODIFICATION OF SPECIFIC CYTOCHROME P450 GENES - Compositions and methods for reducing the level of nornicotine and N′-nitrosonornicotine (NNN) in | 05-17-2012 |
| 20120117933 | ALTERATION OF TOBACCO ALKALOID CONTENT THROUGH MODIFICATION OF SPECIFIC CYTOCHROME P450 GENES - Compositions and methods for reducing the level of nornicotine and N′-nitrosonornicotine (NNN) in | 05-17-2012 |
| 20120064010 | CCR3 and its Ligands Are Therapeutic and Diagnostic Targets for Neovascular Age-Related Macular Degeneration - The results presented herein demonstrate the specific expression of CCR3 in CNV endothelial cells in humans with AMD, and despite the expression of its ligands, eotaxin-1, -2, and -3, neither eosinophils nor mast cells are present in human CNV. The genetic or pharmacological targeting of CCR3 or eotaxins as disclosed herein inhibited injury-induced CNV in mice. CNV suppression by CCR3 blockade was due to direct inhibition of endothelial cell proliferation, and was uncoupled from inflammation as it occurred in mice lacking eosinophils or mast cells and was independent of macrophage and neutrophil recruitment. CCR3 blockade was more effective at reducing CNV than vascular endothelial growth factor-A (VEGF-A) neutralization, which is currently in clinical use, and, unlike VEGF-A blockade, not toxic to the mouse retina. In vivo imaging with CCR3-targeting quantum dots located spontaneous CNV invisible to standard fluorescein angiography in mice before retinal invasion. CCR3 targeting is useful in reducing vision loss due to AMD through early detection and therapeutic angioinhibition. | 03-15-2012 |
| 20110268723 | CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration - Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis. | 11-03-2011 |
| 20110263518 | D-Tagatose-Based Compositions and Methods for Preventing and Treating Atherosclerosis, Metabolic Syndrome, and Symptoms Thereof - Pharmaceutical compositions including D-tagatose along with a stilbene or stilbenoid component, or a salt or derivative thereof. Methods of prophylaxis and therapy by administering to a mammal a pharmaceutically effective amount of D-tagatose, optionally in combination with a stilbene or stilbenoid component, or a salt or derivative thereof to prevent or treat atherosclerosis, the metabolic syndrome, obesity, or diabetes. | 10-27-2011 |
| 20110178025 | Amidated Dopamine Neuron Stimulating Peptides for CNS Dopaminergic Upregulation - The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies. | 07-21-2011 |
| 20110174322 | ALTERATION OF TOBACCO ALKALOID CONTENT THROUGH MODIFICATION OF SPECIFIC CYTOCHROME P450 GENES - Compositions and methods for reducing the level of nornicotine and N′-nitrosonornicotine (NNN) in | 07-21-2011 |
| 20110166177 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS - Provided are methods for using bis-quaternary ammonium compounds to treat inflammatory pain, neuropathic pain and nociceptive pain. | 07-07-2011 |
| 20110160694 | Nanotubes as Mitochondrial Uncouplers - A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Ca | 06-30-2011 |
| 20110142938 | Nanotubes as Mitochondrial Uncouplers - A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Ca | 06-16-2011 |
| 20110112130 | Opioid-Nornicotine Codrugs Combinations for Pain Management - The present invention relates to the field of pain management, and more particularly to synergistic codrugs comprising an opioid and nornicotine which have been combined to form a single chemical codrug entity. When the codrug is administered it produces a synergistic analgesic response to pain. | 05-12-2011 |
| 20110105556 | TRIS-QUARTERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS - Provided are tris-quaternary ammonium compounds which are modulators of nicotinic acetylocholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse and or gastrointestinal tract disorders. | 05-05-2011 |
| 20110104724 | BIOMARKERS OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE - A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and/or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu—Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and/or serotransferrin protein; | 05-05-2011 |
| 20110097390 | Ultra-Small RNAs as Toll-Like Receptor-3 Antagonists - Provided are methods and compositions for the treatment or prevention of macular degeneration or other diseases or disorders associated with activation of TLR | 04-28-2011 |
| 20100266540 | DRUG CLASS FOR THE TREATMENT OF CANCER - Compositions, methods, and combination therapies for the treatment of cancers, including lymphomas, leukemias, melanomas, lung cancer, and metastatic disease, are provided. Specifically, compositions comprising ligands to Pgrmc1 are disclosed for use in treating and inhibiting tumor growth and progression and inhibition of metastases. The compositions and methods using these ligands can be used alone or in combination with other reagents and cancer treatment modalities. | 10-21-2010 |
| 20100222377 | BIS-QUATERNARY AMMONIUM CYCLOPHANE COMPOUNDS THAT INTERACT WITH NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS - Provided are bis-quaternary ammonium cyclophane compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders. | 09-02-2010 |
| 20100216847 | NORNICOTINE FOR THE TREATMENT OF PAIN - This invention relates to the use of R(+)-, S(−)- or racemic nornicotine for the treatment of pain. | 08-26-2010 |
| 20100184692 | Amidated Dopamine Neuron Stimulating Peptides for CNS Dopaminergic Upregulation - The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies. | 07-22-2010 |
| 20100183585 | METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTASES THROUGH THE MODULATION OF LATEXIN - The present invention relates to methods for treating cancers and metastatic diseases by modulating latexin expression and/or latexin activity. | 07-22-2010 |
| 20100179186 | USE OF A NOVEL ALPHA-7 nAChR ANTAGONIST TO SUPPRESS PATHOGENIC SIGNAL TRANSDUCTION IN CANCER AND AIDS - This application provides a method for the use of select quaternary ammonium antagonists to alpha-7 nAChR for the treatment of cancer and HIV and AIDS. | 07-15-2010 |
| 20100173937 | USE OF TETRAKIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS - Provided are methods of modulating, treating, reversing and/or preventing pain using tetrakis quaternary ammonium compounds, especially regarding pain of central and/or peripheral origin and/or pain which is nociceptive, neuropathic, somatic, visceral, and/or inflammatory in nature. | 07-08-2010 |
| 20100152237 | BIS-PYRINDINO CONTAINING COMPOUNDS FOR THE USE IN THE TREATMENT OF CNS PATHOLOGIES - N-n-Alkylation of nicotine converts nicotine from an agonist into an antagonist specifically for neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogs exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for the blood-brain barrier choline transporter. | 06-17-2010 |
| 20100120857 | USE OF TRIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS - Provided are tris-quaternary ammonium compounds which are modulators of nociception and pain. | 05-13-2010 |
| 20100113511 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors - Provided are monoquaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders. | 05-06-2010 |
| 20100105067 | BIOMARKERS FOR OVARIAN CANCER - The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as ovarian cancer, ovarian cancer of low malignant potential, benign ovarian disease or other malignant condition. The biomarkers can be detected by SELDI mass spectrometry. | 04-29-2010 |
| 20100098274 | METHOD AND SYSTEM FOR CREATING THREE-DIMENSIONAL SPATIAL AUDIO - A system and method for rendering a virtual sound source using a plurality of speakers in an arbitrary arrangement includes expanding a wave field of the virtual sound source and a composite wave field generated by the plurality of speakers into multi-pole expansions, and equating the multi-pole expansions to each other to form a continuous equation. A set of constraints is applied to the continuous equation that minimize an error in a sweet spot region resulting in a linear system of equations. The linear system of equations is solved using singular-value decomposition to arrive at a pseudo-inverse representing a multi-dimensional transfer function between the virtual sound source and the plurality of speakers. The multi-dimensional transfer function is then applied to a signal of the virtual sound source to render the virtual sound source in the sweet spot region using the plurality of speakers in the arbitrary arrangement. | 04-22-2010 |
| 20100087657 | ENANTIOSELECTIVE SYNTHESIS OF (+) AND (-)-2-[1-(2,6-DICHLOROPHENOXY)-ETHYL]-1,3-DIAZACYCLOPENT-2-3ENE - This application provides a method for the enantioselective synthesis of (+) and (−) lofexidine or 2-[1-(2,6)-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene. | 04-08-2010 |
| 20100086973 | GLYCOSYLATE DERIVATIVES OF MITHRAMYCIN, METHOD OF PREPARATION AND USES THEREOF - The present invention provides compounds characterized by the formula (I), where each of the substituent radicals is described in the specification. The invention also describes the use of said compounds in the treatment of various diseases, including: cancer or tumoral processes in general, Paget's disease, hypercalcaemia, hypercalciuria and neurological diseases (inter alia, Parkinson's, Alzheimer's, Huntington's). | 04-08-2010 |
| 20100081678 | INDOLE COMPOUNDS AND THEIR USE AS RADIATION SENSITIZING AGENTS AND CHEMOTHERAPEUTIC AGENTS - Indole derivatives that are useful in the treatment of cancer as a chemotherapeutic agent or radiosensitizing agent. | 04-01-2010 |
| 20100069432 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors - Provided are bis-quaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders. | 03-18-2010 |
| 20100048605 | SYNERGISTIC EFFECTS OF COMBINATIONS OF NORNICOTINE AND OPIOIDS FOR THE TREATMENT OF PAIN - This invention relates to pharmaceutical compositions and methods where S(−)-nornicotine, R(+)-nornicotine, or racemic nornicotine are co-administered with an opioid analgesic in amounts effective to cause or enhance a synergistic analgesic response to treat pain (including acute, chronic, and cancer related pain). Preferably the coadministration of nornicotine with the opioid results in decreased dependence and tolerance potential as well as diminishing side effects, compared to conventional opioid therapy. | 02-25-2010 |
| 20100041120 | Botryoccocus braunii Triterpene Synthase Proteins and Nucleic Acid Molecules, and Methods for Their Use - This application relates to the functional identification and characterization of a nucleic acid molecule encoding a triterpene synthase, in particular botryococcene synthase. Also described are host cells comprising the nucleic acid molecules of this invention, proteins encoded by the nucleic acid molecules and methods for using the nucleic acid molecules, transformed hosts and encoded proteins to produce high levels of triterpene hydrocarbons. | 02-18-2010 |
| 20100035820 | AMIDATED DOPAMINE NEURON STIMULATING PEPTIDES FOR CNS DOPAMINERGIC UPREGULATION - The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies. | 02-11-2010 |
| 20100031990 | Cascaded Photovoltaic and Thermophotovoltaic Energy Conversion Apparatus with Near-Field Radiation Transfer Enhancement at Nanoscale Gaps - A cascaded photovoltaic/thermophotovoltaic energy conversion apparatus, a cascaded thermophotovoltaic energy conversion apparatus, and a method for forming the apparatuses are provided. The cascaded photovoltaic/thermophotovoltauc apparatus includes a photovoltaic device that receives solar radiation on an upper surface thereof and produces a first electric current output and a thermal radiation output, and a thermophotovoltaic device disposed a predetermined distance below a lower surface of the photovoltaic device, the thermophotovoltaic device receiving the thermal radiation output and converting the received thermal radiation output into a second electric current output. The cascaded thermophotovoltaic apparatus includes a radiator maintained at constant temperature via an external heat input on its upper surface and produces a thermal radiation output, and a thermophotovoltaic device disposed a predetermined distance below a lower surface of the radiator, the thermophotovoltaic device receiving the thermal radiation output and converting the received thermal radiation output into a first electric current output. | 02-11-2010 |
| 20100009423 | B. BRAUNII, RACE B GENE FOR A TRITERPENE METHYLTRANSFERASE ENZYME AND USES THEREOF - Provided is an isolated polypeptide having triterpene methyltransferase activity. Also provided is an isolated nucleic acid molecule that encodes the triterpene methyltransferase polypeptides; a vector comprising the nucleic acid molecules that encode the triterpene methyltransferase polypeptides; and a host cell(s) transfected with the aforementioned nucleic acid molecule or vector. In another aspect, a method of producing a methylated triterpene is provided. The method comprises providing a metabolizable carbon source to a host cell transfected with a nucleic acid molecule that encodes a triterpene methyltransferase under conditions sufficient for production of a methylated triterpene. The method optionally further comprises isolating the methylated triterpene produced by the host cell. | 01-14-2010 |
| 20090281038 | Phylloplanins Inhibition of Microbial Growth on Organic Materials - The present invention relates to plant proteins produced by a plant's epidermal layer that contribute to the innate pest/disease resistance of the plant (“phylloplanins’), compositions comprising the phylloplanins and methods of using the them. In particular the methods relate to inhibiting or prevent microbial, e.g., fungal or bacterial, growth on a subject, organism or surface, particularly inhibiting or preventing spoilage of food products due to microbial infection and growth. The invention also relates to transformed host cells that produce the phylloplanins, and to transgenic plants producing phylloplanins conferring increased resistance to microbial infections/growth. | 11-12-2009 |
| 20090263804 | Biomarkers for aging - A statistical and functional correlation strategy to identify changes in cellular pathways specifically linked to impaired cognitive function with aging. Analyses using the strategy identified multiple groups of genes expressed in the hippocampi of mammals, where the genes were expressed at different levels for several ages. The aging changes in expression began before mid-life. Many of the genes were involved in specific neuronal and glial pathways with previously unrecognized relationships to aging and/or cognitive decline. These identified genes and the proteins they encode can be used as novel biomarkers of brain aging and as targets for developing treatment methods against age-related cognitive decline, Alzheimer's Disease and Parkinson's Disease. | 10-22-2009 |
| 20090260091 | Methods and animal model for analyzing age-related macular degeneration - Methods for testing candidate drugs for treatment of age-related macular degeneration are provided. Ccl2-deficient, and Ccr2-deficient mice are used to determine the effect of candidate drugs and treatments on development of age-related macular degeneration. Also provided is a Ccl2-deficient, Ccr2-deficient dual knockout mouse, which is a useful animal model for age-related macular degeneration. | 10-15-2009 |
| 20090238793 | TOLL LIKE RECEPTOR (TLR) STIMULATION FOR OCULAR ANGIOGENESIS AND MACULAR DEGENERATION - Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of stimulators of the TLR3 and TLR7 receptors, Trif or of IL-10 and IL-12 inhibits ocular angiogenesis. Furthermore, all siRNAs (both targeted and non-targeted) can inhibit ocular angiogenesis. | 09-24-2009 |
| 20090215667 | Utility of phylloplanins as antibiotics, selective fungicides and for enhancing microbial resistance in plants - The present invention relates to plant proteins produced by a plant's epidermal layer that contribute to the innate pest/disease resistance of the plant (“phylloplanins”), compositions comprising the phylloplanins and methods of using them. In particular the methods relate to inhibiting or preventing microbial, e.g., fungal or bacterial, growth on a subject, organism or surface by administering a phylloplanin. The invention also relates to transformed host cells that produce phylloplanins, and to transgenic plants producing phylloplanins conferring increased resistance to microbial infections/growth. | 08-27-2009 |
| 20090205072 | ALTERATION OF TOBACCO ALKALOID CONTENT THROUGH MODIFICATION OF SPECIFIC CYTOCHROME P450 GENES - Compositions and methods for reducing the level of nornicotine and N′-nitrosonornicotine (NNN) in | 08-13-2009 |
| 20090202510 | ALTERED SUMOYLATION OF LAMIN A PROTEIN ASSOCIATED WITH DILATED CARDIOMYOPATHY - This invention relates to methods of diagnosing dilated cardiomyopathy using analysis of the lamin A protein and sumylation of same, as well as methods for treating dilated cardiomyopathy, comprising enhancing the sumoylation of the lamin A protein in a subject in need thereof. | 08-13-2009 |
| 20090196918 | Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions - Provided is a liposome comprising a hydrophobic lactone drug and a cyclodextrin, wherein the liposome has an intraliposomal pH and cyclodextrin concentration such that upon administration of the liposome to a subject, the liposome exhibits a uniform release profile of the hydrophobic lactone drug. Also provided is a method of administering a hydrophobic lactone drug to a subject in need thereof. The method comprises administering a liposome to the subject in need, wherein the liposome comprises the hydrophobic lactone drug and a cyclodextrin. The liposome has an intraliposomal pH and cyclodextrin concentration such that upon administration of the liposome to the subject, the liposome exhibits a uniform release profile of the hydrophobic lactone drug. | 08-06-2009 |
| 20090196917 | Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions - Disclosed herein is a liposomal formulation that comprises a liposome and a liquid carrier. In the liposomal formulation, the liposome comprises a hydrophobic lactone drug and has an intraliposomal metal ion concentration higher than the metal ion concentration of the liquid carrier. Also disclosed herein is a method for active loading of a hydrophobic lactone drug into a liposome. The method includes preparing a liposome in the presence of a metal salt solution, an acid form of a counterion of the metal salt being membrane permeable, such that the liposome preparation contains entrapped metal ion. The method further includes forming a liposome with high intraliposomal pH by separating extravesicular metal salt solution from the liposome by exposing the liposome to a metal salt-free solution, resulting in diffusion of the acid form of the counterion out of the liposome and formation of an intraliposomal pH higher than that of the metal salt-free solution. The method also includes exposing the liposome with high intraliposomal pH to an isoosmolal solution containing a hydrophobic lactone drug, the isoosmolal solution having a pH lower than the intraliposomal pH, such that the hydrophobic lactone drug accumulates in the liposome predominantly in its ring-opened form. | 08-06-2009 |
| 20090181445 | Crystallization and Structure of a Plant Peptide Deformylase - This invention relates to the crystal structure of a plant peptide deformylase polypeptide and methods of using the structure to design compounds that modulate the activity of the polypeptide. | 07-16-2009 |
| 20090170865 | Treatment of Prostate Cancer with Angiogenesis-Targeting Quinazoline-Based Anti-Cancer Compounds - Provided is a method of inhibiting the growth of prostate cancer cells comprising administering an effective amount of DZ-50 (2-[4-biphenyl-4-sulfonyl)-piperazin-1-yl]-6,7-diisopropoxyquinazolin-4-yl-amine) to a patient in need thereof. In another aspect, a method is provided for inhibiting the initiation of prostate cancer comprising administering an effective amount of DZ-50 to a patient in need thereof. In yet another aspect, a method is provided for inhibiting the formation of a prostate tumor-derived metastatic lesion comprising administering an effective amount of DZ-50 to a patient in need thereof. In any of the aforementioned methods, a quinazoline-based drug which induces apoptosis of a prostate cancer cell may be coadministered with DZ-50. Also provided is a composition comprising DZ-50, a quinazoline-based drug which induces apoptosis of a prostate cancer cell, and a pharmaceutically acceptable carrier. | 07-02-2009 |
| 20090143424 | TETRAKIS-QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACTEYLCHOLINE RECEPTORS - Provided are tetrakis-quaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders. | 06-04-2009 |
| 20090133133 | Transgenic Mice for Bioassay of Prions from Deer and Elk with Chronic Wasting Disease - The invention relates to the use of transgenic constructs to produce animal models for the study of chronic wasting disease. | 05-21-2009 |
| 20090123375 | CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration - Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis. | 05-14-2009 |
| 20090117054 | SUBLINGUAL SPRAY FOR THE TREATMENT OF PAIN - This invention relates to a spray for sublingual administration, used in the treatment and management of pain, especially acute pain. Also provided are methods of treatment and management of pain, a metered dosage system for administration of the spray, and combination therapies. | 05-07-2009 |
| 20090070901 | Modified rubisco large subunit n-methyltransferase useful for targeting molecules to the active-site vicinity of ribulose-1, 5-bisphosphate - The present invention generally relates to a modified Rubisco large subunit | 03-12-2009 |
| 20090028831 | STEM CELL REGULATOR, COMPOSITIONS AND METHODS OF USE - The disclosure provides methods and compositions comprising Slit2 agonists and antagonists useful for modulating hematopoietic stem cell (HSC) proliferation and growth. In some aspects, the disclosure provides methods and compositions for stimulating HSC proliferation in vivo, ex vivo, or in vitro. In other aspects, the disclosure provides methods and compositions for inhibiting HSC proliferation. | 01-29-2009 |
| 20090017102 | Enhancing transdermal delivery of opiod antagonists and agonistis using codrugs links to bupropion or hydroxybupropion - The present invention is directed to novel codrugs comprising bupropion or hydroxybupropion and an opioid antagonist or an opioid agonist joined together by chemical bonding. The codrugs provide a significant increase in the transdermal flux across human skin, as compared to the basic opioid antagonist or opioid agonist. | 01-15-2009 |
| 20080299130 | Methods And Compositions For The Treatment Of Ocular Neovascularization - The invention relates to compositions and methods for the treatment or prevention of ocular neovascularization by reducing macrophage infiltration into the eye. The compositions of the invention include an antagonist of MCP-1 and/or CCR2 that blocks MCP-1 binding to or activation of CCR2y. | 12-04-2008 |
| 20080287490 | Bis-pyridino containing compounds for the use in the treatment of CNS pathologies - N-n-Alkylation of nicotine converts nicotine from an agonist into an antagonist specifically for neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogs exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for the blood-brain barrier choline transporter. | 11-20-2008 |
| 20080202541 | Alteration of tobacco alkaloid content through modification of specific cytochrome P450 genes - Compositions and methods for reducing the level of nornicotine and N′-nitrosonornicotine (NNN) in | 08-28-2008 |
| 20080201796 | Transformed plants accumulating mono-and/or sesquiterpenes - The present invention relates to plant expressing transgenes and to plants transformed to comprise additional copies of genes, said genes encoding at least a HMGR-CoA reductase and a terpene synthase. The invention further claims methods for preparing the plants, and a method for producing terpenes. The present thus provides a reliable and cost effective platform for generating any terpene, in particular any mono- and/or sesquiterpene of interest. For example, the skilled person may use any gene encoding a sesquiterpene synthase for accumulating the respective sesquiterpene in the plant of the present invention. | 08-21-2008 |
